Related Experiment Video

Updated: May 20, 2026

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia?

Narges Moslemi Zadeh1, Farshad Naghshvar, Sepideh Peyvandi

  • 1OB/GYN Department, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.

ISRN Obstetrics and Gynecology
|July 11, 2012
PubMed

Insights

Predicting preeclampsia early is possible using placenta protein 13 (PP13) and pregnancy-associated plasma protein A (PAPP-A) levels. Measuring these biomarkers, especially their combined values, in early pregnancy significantly aids in early diagnosis.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Biochemistry

Background:

  • Preeclampsia affects 5-6% of pregnancies globally.
  • Early diagnosis of preeclampsia is crucial for effective management.
  • Predictive factors are essential for identifying high-risk pregnancies.

Purpose of the Study:

  • To assess the predictive value of placenta protein 13 (PP13) and pregnancy-associated plasma protein A (PAPP-A) for early preeclampsia diagnosis.
  • To evaluate these biomarkers in both the first and second trimesters of pregnancy.

Main Methods:

  • A case-control study involving 1500 pregnant women in Sari, Iran (2010-2011).
  • Blood samples collected during 11-13 and 24-28 weeks of gestation.
  • Serum levels of PAPP-A and PP13 measured in women who developed preeclampsia (cases) and healthy controls.

Main Results:

  • Significantly lower serum levels of PAPP-A and PP13 were observed in both trimesters for women who developed preeclampsia (P < 0.001).
  • A cumulative value of the four variables with a cut-off of 238.5 demonstrated high diagnostic accuracy (91.0% sensitivity, 91.0% specificity, 0.968 AUC).

Conclusions:

  • Measuring PAPP-A and PP13 in early pregnancy (first and second trimesters) is beneficial for predicting preeclampsia.
  • The cumulative assessment of these biomarkers in both trimesters offers the most effective diagnostic value for preeclampsia incidence.

More Related Videos

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...